# Oxagen

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/oxagen

- Industry: Pharmaceuticals
- Headquarters: Abingdon, UK
- Website: www.oxagen.co.uk
- Total disclosed funding: $100M
- Latest round: Series C (Jun 16, 2010)
- Investors on record: 12

## About

Oxagen Ltd. is a UK-based biotechnology company specializing in innovative therapies and diagnostic tools aimed at addressing healthcare challenges and improving patient outcomes across Europe and North America.Founded in 1997, Oxagen Ltd. is headquartered in Abingdon, UK, and operates in the biotechnology sector, focusing on developing solutions for specific health conditions. The company has completed 8 deals, with its most recent funding round occurring on June 16, 2010, where they raised GBP 4.5 million in a Series C round led by Wellington Partners, bringing the total amount raised to GBP 4.5 million with a current valuation of GBP 54.43 million.Oxagen.co.uk specializes in advanced biotechnology solutions for health and wellness, offering a range of innovative therapies and diagnostic tools aimed at enhancing patient outcomes. Their products are designed to address specific health conditions, benefiting healthcare providers and patients alike, and are marketed to hospitals, medical practitioners, and research institutions across Europe and North America.In 2016, Oxagen.co.uk reported a revenue of GBP 0, with an EBITDA of GBP -8,653.9.In June 2010, Oxagen Ltd. secured GBP 4.5 million in funding through its Series C round, which will support the development of new products aimed at expanding their offerings. The company plans to enter new markets and geographical regions, though specific targets and timelines have not been disclosed. This funding aims to enhance their capabilities and support ongoing research initiatives, enabling future growth.

## Funding rounds

- Series C, Jun 16, 2010, $6.5M — Wellington Partners
- Series C, Nov 20, 2009, $26M — Wellcome Trust, Novartis Venture Fund, Advent Venture Partners, SV Health Investors, Red Abbey, Bessemer Venture Partners, O-Bank, Omega Advisors, MPM BioImpact
- Series B, May 18, 2005, $60M — 3i, Abingworth, Wellcome Trust, Advent Venture Partners, SV Health Investors, Red Abbey, Bessemer Venture Partners, O-Bank, MPM BioImpact
- Seed, Apr 1, 1997, $6.9M — 3i, Wellcome Trust, Advent Venture Partners

## Investors

- 3i (https://capitalatlas.ai/funds/3i) — Seed, Series B
- Wellcome Trust — Seed, Series B, Series C
- Advent Venture Partners (https://capitalatlas.ai/funds/advent-venture-partners) — Seed, Series B, Series C
- Abingworth (https://capitalatlas.ai/funds/abingworth) — Series B
- SV Health Investors (https://capitalatlas.ai/funds/sv-health-investors) — Series B, Series C
- Red Abbey (https://capitalatlas.ai/funds/red-abbey) — Series B, Series C
- Bessemer Venture Partners (https://capitalatlas.ai/funds/bessemer-venture-partners) — Series B, Series C
- O-Bank (https://capitalatlas.ai/funds/o-bank) — Series B, Series C
- MPM BioImpact (https://capitalatlas.ai/funds/mpm-bioimpact) — Series B, Series C
- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series C
- Omega Advisors (https://capitalatlas.ai/funds/omega-advisors) — Series C
- Wellington Partners (https://capitalatlas.ai/funds/wellington-partners) — Series C